XTX Topco Ltd Takes $599,000 Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

XTX Topco Ltd purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,251 shares of the medical research company’s stock, valued at approximately $599,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Eagle Asset Management Inc. lifted its position in shares of Bio-Rad Laboratories by 1.0% during the 4th quarter. Eagle Asset Management Inc. now owns 2,225 shares of the medical research company’s stock worth $939,000 after buying an additional 23 shares in the last quarter. Mather Group LLC. increased its position in shares of Bio-Rad Laboratories by 6.8% during the first quarter. Mather Group LLC. now owns 377 shares of the medical research company’s stock valued at $212,000 after acquiring an additional 24 shares during the last quarter. Park Place Capital Corp increased its position in shares of Bio-Rad Laboratories by 6.3% during the first quarter. Park Place Capital Corp now owns 419 shares of the medical research company’s stock valued at $201,000 after acquiring an additional 25 shares during the last quarter. Raymond James Trust N.A. increased its position in shares of Bio-Rad Laboratories by 5.5% during the first quarter. Raymond James Trust N.A. now owns 501 shares of the medical research company’s stock valued at $283,000 after acquiring an additional 26 shares during the last quarter. Finally, Texas Permanent School Fund increased its position in shares of Bio-Rad Laboratories by 0.9% during the fourth quarter. Texas Permanent School Fund now owns 3,059 shares of the medical research company’s stock valued at $1,286,000 after acquiring an additional 27 shares during the last quarter. 63.98% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Down 2.7 %

Bio-Rad Laboratories stock opened at $357.91 on Monday. Bio-Rad Laboratories, Inc. has a 1-year low of $344.63 and a 1-year high of $514.25. The firm has a market capitalization of $10.41 billion, a price-to-earnings ratio of -23.84 and a beta of 0.89. The company has a current ratio of 5.39, a quick ratio of 4.06 and a debt-to-equity ratio of 0.14. The firm has a 50 day simple moving average of $393.29 and a 200 day simple moving average of $415.98.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, August 3rd. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.55 by $0.45. Bio-Rad Laboratories had a positive return on equity of 4.02% and a negative net margin of 15.52%. The business had revenue of $681.10 million during the quarter, compared to the consensus estimate of $697.96 million. During the same quarter last year, the company earned $3.38 EPS. The firm’s revenue was down 1.4% compared to the same quarter last year. On average, analysts predict that Bio-Rad Laboratories, Inc. will post 12.93 earnings per share for the current year.

Insiders Place Their Bets

In other Bio-Rad Laboratories news, EVP Timothy S. Ernst sold 2,350 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $395.60, for a total value of $929,660.00. Following the sale, the executive vice president now directly owns 2,416 shares in the company, valued at approximately $955,769.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Bio-Rad Laboratories news, EVP Timothy S. Ernst sold 2,350 shares of the company’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $395.60, for a total value of $929,660.00. Following the transaction, the executive vice president now directly owns 2,416 shares in the company, valued at approximately $955,769.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Crowley sold 500 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $379.39, for a total value of $189,695.00. Following the completion of the transaction, the executive vice president now owns 6,040 shares in the company, valued at $2,291,515.60. The disclosure for this sale can be found here. Insiders have sold 3,150 shares of company stock worth $1,234,762 in the last three months. 17.06% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BIO. Wells Fargo & Company reduced their price target on shares of Bio-Rad Laboratories from $550.00 to $525.00 and set an “overweight” rating for the company in a research report on Monday, August 7th. Royal Bank of Canada upped their price objective on Bio-Rad Laboratories from $522.00 to $524.00 and gave the company an “outperform” rating in a research note on Friday, August 4th. StockNews.com started coverage on Bio-Rad Laboratories in a research note on Thursday, August 17th. They issued a “buy” rating on the stock. Finally, Credit Suisse Group dropped their price objective on Bio-Rad Laboratories from $580.00 to $550.00 and set an “outperform” rating on the stock in a research note on Friday, August 4th. Four equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $533.00.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.